Vaccines
39
1
3
30
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
2.6%
1 terminated out of 39 trials
96.8%
+10.3% vs benchmark
26%
10 trials in Phase 3/4
20%
6 of 30 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 30 completed trials
Clinical Trials (39)
Korea Comirnaty Post-marketing Surveillance
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age
Increasing Men's Engagement in Preventive Healthcare Through an Enhanced Cocoon Vaccination Strategy
The Next Generation Vaccine Card: Innovative Technology to Improve Vaccine Equity in Rural and Urban Settings in East Africa
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
A Multifaceted Intervention on Reducing Immunization Errors
Boost Intentions and Facilitate Action to Promote COVID-19 Booster Take-up
Effects of Prompt to Bundle COVID-19 Booster and Flu Shot
Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake
Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy Volunteers
Safety and Immunogenicity of AdCLD-CoV19-1 OMI as a Booster: A SARS-CoV-2 (COVID-19) Preventive Vaccine
Coordinated Vaccination Against RSV and Influenza in Patients With Chronic Heart Failure and Its Impact on Prognosis.
Immunogenicity Evaluation of Omicron Variant-based Vaccine and a Trivalent Vaccine in Adults Against COVID-19 in Chile
Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1
Medicine-induced Cardiac Hemodialysis on COVID-19
Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan
Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile